Findings from DUO-E, "the first phase III study to examine the combination of immunotherapy and PARP inhibition in endometrial cancer" was recently presented at the European Society of Medical Oncology (ESMO) Congress. The DUO-E study, consisting of 718 randomized patients, found statistically significant progress-free survival (PFS) when durvalumab, alone and in combination with olaparib, were used in the intent-to-treat population.
To learn more about the DUO-E study, click here.
Sources mentioned:
- Westin SN, Moore K, Chon HS, et al. on behalf of the DUO-E investigators. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. JCO; Published online 21 October 2023. DOI: 10.1200/JCO.23.02132
- LBA41 - Westin SN, Moore KN, Chon HS, et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. Ann Oncol 2023;34(Suppl_2):S1282–S1283. DOI: https://doi.org/10.1016/j.annonc.2023.10.035
No comments:
Post a Comment